表紙
市場調查報告書

類升糖素胜肽2 (GLP2R) :開發中產品分析

Glucagon Like Peptide 2 Receptor - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 386360
出版日期 內容資訊 英文 65 Pages
訂單完成後即時交付
價格
類升糖素胜肽2 (GLP2R) :開發中產品分析 Glucagon Like Peptide 2 Receptor - Pipeline Review, H2 2019
出版日期: 2019年12月27日內容資訊: 英文 65 Pages
簡介

本報告提供以類升糖素胜肽2 (GLP2R) 為目標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您涵括了最新的新聞與發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

類升糖素胜肽2 (GLP2R)的概要

治療藥的開發

  • 開發中的產品 - 各開發階段
  • 開發中的產品 - 各治療範圍
  • 開發中的產品 - 各適應症

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的評估

  • 單劑療法/聯合治療產品別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Naia Limited
  • Shire Plc
  • Tasly Pharmaceutical Group Co., Ltd.
  • Zealand Pharma A/S

藥物簡介

暫停中的計劃

主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC2215TDB

Summary

Glucagon Like Peptide 2 Receptor (GLP2R) - Glucagon-like peptide 2 receptor (GLP-2R) is a protein encoded by the GLP2R gene. GLP2R, a G protein-coupled receptor superfamily member is expressed in the gut. GLP2 stimulates intestinal growth and up regulates villus height in the small intestine, concomitant with increased crypt cell proliferation and decreased enterocyte apoptosis. GLP2 prevents intestinal hypoplasia resulting from total parenteral nutrition.

Glucagon Like Peptide 2 Receptor (GLP2R) pipeline Target constitutes close to 15 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 1, 4, 5, 1 and 1 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Gastrointestinal, Toxicology, Immunology, Musculoskeletal Disorders and Other Diseases which include indications Short Bowel Syndrome, Chemotherapy Effects, Chemotherapy-Induced Diarrhea (CID), Crohn's Disease (Regional Enteritis), Gastrointestinal Mucositis, Inflammation, Multiple Organ Failure (Multiple Organ Dysfunction Syndrome) and Osteoporosis.

The latest report Glucagon Like Peptide 2 Receptor - Pipeline Review, H2 2019, outlays comprehensive information on the Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Glucagon Like Peptide 2 Receptor (GLP2R)
  • The report reviews Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Glucagon Like Peptide 2 Receptor (GLP2R)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Glucagon Like Peptide 2 Receptor (GLP2R) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Glucagon Like Peptide 2 Receptor (GLP2R) - Overview
  • Glucagon Like Peptide 2 Receptor (GLP2R) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Glucagon Like Peptide 2 Receptor (GLP2R) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Glucagon Like Peptide 2 Receptor (GLP2R) - Companies Involved in Therapeutics Development
  • Adocia SAS
  • Bainan Biotech ApS
  • Hanmi Pharmaceuticals Co Ltd
  • Huons Global Co Ltd
  • Naia Rare Diseases Inc
  • OPKO Health Inc
  • Pfizer Inc
  • PhaseBio Pharmaceuticals Inc
  • Sosei Heptares
  • Takeda Pharmaceutical Co Ltd
  • Zealand Pharma AS
  • Glucagon Like Peptide 2 Receptor (GLP2R) - Drug Profiles
  • apraglutide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Drugs to Agonize GIP and GLP-2 for Osteoporosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • elsiglutide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Fusion Protein to Agonize GLP2R for Short Bowel Syndrome - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • glepaglutide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • HL-06 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • HM-15912 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MOD-1501 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NB-1002 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Peptide to Agonize GLP2R for Intestinal Diseases - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TAK-681 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • teduglutide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • teduglutide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • teduglutide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ZP-7570 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Glucagon Like Peptide 2 Receptor (GLP2R) - Dormant Products
  • Glucagon Like Peptide 2 Receptor (GLP2R) - Product Development Milestones
  • Featured News & Press Releases
  • Jun 26, 2019: Zealand Pharma doses first subject in Phase 1 clinical trial with potential next generation dual-acting peptide therapeutic for short bowel syndrome
  • May 17, 2019: Therachon to present data from ongoing Phase II Study of Apraglutide for Short Bowel Syndrome at Digestive Disease Week
  • May 17, 2019: U.S. FDA approves GATTEX (teduglutide) for children 1 year of age and older with Short Bowel Syndrome
  • May 07, 2019: Zealand Pharma enrolls first patient in Phase 3 extension study of glepaglutide for treatment for short bowel syndrome
  • May 03, 2019: Hanmi's short bowel syndrome treatment becomes orphan drug in US
  • Mar 25, 2019: Therachon presents data from preclinical and phase I clinical studies of Apraglutide for the treatment of Short Bowel Syndrome at ASPEN 2019 Nutrition Science & Practice Conference
  • Feb 05, 2019: Pharm-Olam enrolls patients in Zealand Pharma orphan drug study
  • Jan 16, 2019: Therachon is granted Orphan Drug Designation by US FDA for Apraglutide for the treatment of Short Bowel Syndrome
  • Nov 29, 2018: Therachon is granted Orphan Drug Designation in the European Union for apraglutide for the treatment of short bowel syndrome
  • Nov 13, 2018: U.S. FDA accepts for filing Shire's supplemental New Drug Application for GATTEX (teduglutide [rDNA origin]) for children with Short Bowel Syndrome
  • Oct 05, 2018: Zealand Pharma enrols first patient in Phase lll study of glepaglutide
  • May 31, 2018: Zealand Pharma to present new clinical Phase 2 results on glepaglutide for the treatment of short bowel syndrome at the DDW conference in the U.S.
  • Apr 26, 2018: Zealand announces successful End-of-Phase 2 meeting with FDA on glepaglutide for short bowel syndrome
  • Apr 09, 2018: Revestive is accepted for restricted use within NHS Scotland
  • Jan 23, 2018: New clinical evidence support potential for glepaglutide as a once-weekly drug for short bowel syndrome
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indication, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Adocia SAS, H2 2019
  • Pipeline by Bainan Biotech ApS, H2 2019
  • Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2019
  • Pipeline by Huons Global Co Ltd, H2 2019
  • Pipeline by Naia Rare Diseases Inc, H2 2019
  • Pipeline by OPKO Health Inc, H2 2019
  • Pipeline by Pfizer Inc, H2 2019
  • Pipeline by PhaseBio Pharmaceuticals Inc, H2 2019
  • Pipeline by Sosei Heptares, H2 2019
  • Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
  • Pipeline by Zealand Pharma AS, H2 2019
  • Dormant Projects, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019